Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Depomed Inc (NASDAQ: DEPO) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Depomed Inc (NASDAQ: DEPO) concerning whether a series of statements by Depomed Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On August 7, 2017, the Company announced that it received a request for information relating to the promotion of opioids from the U.S. Senate Committee on Homeland Security and Governmental Affairs, as well as from the Office of the Attorney General of Maryland and the U.S. Department of Justice.

Following this news, NASDAQ: DEPO has fallen as much as $2.68, or 29.04%, during intraday trading on August 8, 2017.

Based in Newark, California, and founded in 1995 Depomed Inc a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States.

If you purchased shares of Depomed Inc (NASDAQ: DEPO) on or before August 7, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185